Greenstone Biosciences的动态

small molecule as control for T cell activities... anti-tumor and off-target toxicity...

Scientists from the UC San Diego have taken a novel approach to #nanoparticle drug delivery to the lungs. Lung metastasis poses a formidable challenge in the realm of cancer treatment, with conventional chemotherapy often falling short due to limited targeting and low accumulation in the lungs. In this article, researches take a microrobot approach using motile algae for localized delivery of drug-loaded nanoparticles to address lung metastasis challenges. The biohybrid microrobot [denoted “algae-NP(DOX)-robot”] combines green microalgae with red blood cell membrane–coated nanoparticles containing doxorubicin, a representative chemotherapeutic drug. Microalgae provide autonomous propulsion in the lungs, leveraging controlled drug release and enhanced drug dispersion to exert antimetastatic effects. Upon intratracheal administration, algae-NP(DOX)-robots efficiently transport their drug payload deep into the lungs while maintaining continuous motility. This strategy leads to rapid drug distribution, improved tissue accumulation, and prolonged retention compared to passive drug-loaded nanoparticles and free drug controls. In a melanoma lung metastasis model, algae-NP(DOX)-robots exhibit substantial improvement in therapeutic efficacy, reducing metastatic burden and extending survival compared to control groups. Be sure to not that this was performed through intratracheal administration, opposed to nebulized delivery. https://lnkd.in/gESp_6DZ #microbots #LNP #PNP #DDS #CRS #CRS2024 #precisionmedicine #innovation #drugdevelopment #cancer #cancerresearch #chemotherapy

NKGen announced details disclosed in today's presentation at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit, including additional information on the scientific rationale, preclinical and clinical data to date on the use of SNK01 enhanced NK cell therapy in patients with advanced AD and with PD. Highlights include: - In vitro studies with SNK01 have shown a direct ability to phagocytose and digest amyloid beta and alpha-synuclein proteins while also secreting immunoregulatory cytokines and identifying and eliminating autoreactive T cells that contribute to neuroinflammation. - SNK01 autologous NK cell therapy was well tolerated and demonstrated a positive effect on cerebral spinal fluid (“CSF”) and plasma levels of Tau, amyloid beta, and alpha-synuclein proteins in Alzheimer’s patients suggesting a potential larger application in the treatment of other neurodegenerative diseases associated with these proteins. - 90% of patients enrolled in the proof-of-concept Phase 1 Alzheimer’s trial had improved or stable cognitive function at week 11 using the composite ADCOMS score. - SNK01 was also found to reduce neuroinflammation, showing improved levels of Glial Fibrillary Acid Protein (GFAP) in most patients, and of Neurofilament-light (NfL), Growth/Differentiation Factor-15 (GDF15), and Latent Transforming Growth Factor Beta Binding Protein 2 (LTBP2) in some patients, suggesting a potential preventative clinical application for SNK01. - NKGen anticipates to begin enrollment for its Phase 2 trial in advanced Alzheimer’s disease in Q2 2024 and submitted an IND for SNK01 in Parkinson’s disease in Q1 2024. For full press release: https://bit.ly/3xTgweO #ParkinsonsDisease #AlzheimersDisease #NeurodegenerativeDisease #NKCellTherapy

?? New Publication Alert! ?? Excited to share a groundbreaking study led by Dr. Berend Snijder, exploring innovative ways to tackle glioblastoma through the repurposing of neuroactive drugs. ???? In this comprehensive study, over 2,500 ex vivo drug responses were profiled across 27 glioblastoma patients and 132 drugs using a clinically concordant, single-cell resolved platform. The research identified a range of neuroactive compounds with potent anti-glioblastoma effects, validated in multiple model systems. Key highlights include: ?? Neuroactive convergence on the AP-1/BTG pathway, showing significant glioblastoma suppression. ?? In silico screening of more than 1 million compounds with high patient validation accuracy. ?? Vortioxetine, an antidepressant, demonstrated synergy with standard-of-care chemotherapies in vivo. These findings establish a novel, actionable framework for glioblastoma treatment, rooted in its neural origins. ?? If you're interested in the full publication or want to discuss the research further, feel free to reach out or check the link below! ?? #GlioblastomaResearch #NeuroactiveDrugs #CancerResearch #PrecisionMedicine #Oncology #DrugRepurposing #10xGenomics https://lnkd.in/gSJzsMn3

Have you heard of radiopharmaceuticals? ?? Of course, you have, we all have! There have been so many deals going on lately in the field it’s been hard to keep track. Radiopharmaceuticals are a rapidly evolving class of drugs that combine radioactive isotopes with biological molecules to target and treat specific diseases, most notably in oncology and neurology. ?? Over the past few decades, radiopharmaceuticals have undergone a significant transformation. Initially, these drugs were primarily used for imaging, allowing for early diagnosis but with the development of theranostics the field now allows a more integral approach. ?? In today’s article, we take a closer look into radiopharmaceuticals and what to look forward to! ?? https://lnkd.in/dYqyTs-Y #radiopharmaceuticals #oncologybreakthroughs #nuclearmedicine #innovativedrugs #futureofhealthcare #healthcareinnovation #cancertreatment Brian Markison | Lantheus | Suchitra Ghoshal | Clarivate | Back Bay Life Science Advisors | Blue Earth Diagnostics | Bracco Imaging | Life Molecular Imaging | cerveau technologies pvt ltd | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Eli Lilly and Company | GE HealthCare | Sofie Biosciences, Inc. | Fusion Pharmaceuticals | AstraZeneca | Bayer | Novartis | Mariana Oncology | Eckert & Ziegler SE | Perspective Therapeutics

????Biocytogen's advanced humanized mouse models are at the forefront of bridging the gap between preclinical research and clinical trials by incorporating human elements (DNA/protein/signaling cascades). These models provide accurate simulations of human physiological responses, which are crucial for developing life-changing therapies. They enable comprehensive in vivo evaluations of drug efficacy, toxicity, and pharmacokinetics/pharmacodynamics, especially in oncology, autoimmune diseases, metabolic disorders, and neurological conditions. Biocytogen's innovative models accelerate drug development by ensuring consistency and reliability, offering effective strategies for evaluating therapies, including antibody-drug conjugates and bispecific antibody treatments. ?? FREE consultation here: https://lnkd.in/gEcG-SaX #humanizedmice, #preclinical, #geneediting, #invivo, #efficacystudies, #PKPD, #Oncology, #IO, #Autoimmune, #Metabolic, #Neurological, #diseases, #ADCs, #BsAbs

We are happy to share a recent publication in the British Journal of Clinical Pharmacology (British Pharmacological Society), a collaborative effort by Yaping Tu, PhD,?Fengying Zhu, Callum Sloss , Michael Method, Brooke Esteves, Eric Westin?and Anna Berkenblit at ImmunoGen, Inc., along with significant contributions from our qPharmetra team members, Eva Hanze and Max Lagraauw.? ? The study "Population Pharmacokinetic Modeling of Mirvetuximab Soravtansine in Ovarian Cancer Patients"? aimed to develop a population pharmacokinetic model for mirvetuximab soravtansine, enhancing the treatment approach for ovarian cancer.? Important patient characteristics such as body weight and age were found to be influential in treatment outcomes and the study further clarifies dosing recommendations for diverse patient populations.? ?? Our congratulations to Eva, Max, and all collaborators for their great work.? We are committed to continuing our efforts in advancing healthcare through innovative research.? #OncologyResearch #qPharmetra #MedicalInnovation #Pharmacometrics

An Exciting Development in Cell Therapy for Autoimmune Disorders! Century Therapeutics, Inc. secures Funding, and acquires Clade Therapeutics, to support the expansion of its autoimmune pipeline! Here are some of the highlights: ??The incorporation of three preclinical-stage programs from Clade's αβ iT platform, spanning cancer and autoimmune diseases (such as Myasthenia Gravis), will address critical unmet needs! ?? The CALiPSO-1 trial for SLE, (an innovative iPSC-derived iNK cell therapy) is poised for additional regulatory filings in 2024. ??A $60 million private placement led by Bain Capital ensures Century Therapeutics, Inc.'s financial stability into 2026, fueling the development of autoimmune therapies ???CEO, Brent Pfeiffenberger, states "Today's news signifies a transformative milestone for Century, as we accelerate and broaden our research and development initiatives in autoimmune diseases and iPSC-derived cell therapy on a larger scale" Stay tuned as Century Therapeutics, Inc develops its autoimmune disease treatments! #CenturyTherapeutics #Innovation #AutoimmuneDisease #celltherapy #CART #SLE #lupus #biotechnology

In a #partnership with Moderna, now expanded to two undisclosed #autoimmune targets, Carisma Therapeutics aim to simplify #celltherapy by bypassing the need to culture patient cells out of the body. The technique is called in vivo CAR-M therapy. In June, Carisma?received a FDA Fast Track Designation for a CAR-M therapy treating HER2-overexpressing solid tumors. Under this #collaboration, Carisma and Moderna will leverage Carisma’s proprietary CAR-M technology and Moderna’s mRNA/LNP platform to develop novel?in vivo?macrophage engineering approaches in the nominated #autoimmunedisease targets.

Will Summit dethrone Merck in immuno-oncology? Well, let's have the FDA weigh in after US phase 3. Here is a necessary article that people should be aware of - confirmatory phase 3 trials in the US are not automatic wins. There is a history of ex-US drug candidates that fail, notably from China. An uncomfortable reality that clinical trial reporting is different in different countries that hold to different standards. At the end of the day, 5 year overall survival is the key driver for the benefit of cancer patients. BioSpace explains - " With the current results coming from China-only trials, all three experts who spoke with BioSpace agree that the FDA will need to see more data from a diverse population in order to consider approval. The use of China-only data can be skewed by factors such as variation in genetics, less patient follow up and cultural differences in reporting side effects. Bardon emphasized that safety/side effects in particular could be a concern for the FDA when reviewing China-only data. For example, in HARMONI-2, there were very few grade 3 adverse events. “[Adverse events] are probably underestimated compared to what we would see in a Western-based population,” Bardon said. " https://lnkd.in/ehbGcC47